BDX · Becton Dickinson & Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $20.25B | $17.12B |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.82B | $9.54B |
| Gross Profit | $9.93B | $9.13B | $8.17B | $8.48B | $9.43B | $7.58B |
| R&D | $1.26B | $1.19B | $1.24B | $1.26B | $1.34B | $1.10B |
| SG&A | $5.28B | $4.86B | $4.72B | $4.71B | $4.87B | $4.33B |
| Total Operating Expenses | $19.26B | $17.78B | $17.26B | $16.59B | $17.45B | $15.63B |
| D&A | $2.46B | $2.29B | $2.29B | $2.23B | $2.27B | $2.15B |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.80B | $1.48B |
| Interest Expense | $613.00M | $528.00M | $452.00M | $398.00M | $469.00M | $528.00M |
| Income Tax | $203.00M | $300.00M | $132.00M | $148.00M | $150.00M | $111.00M |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874.00M |
| EPS - Basic | $4.58 | $4.62 | $3.91 | $4.66 | $5.31 | $2.11 |
| EPS - Diluted | $4.58 | $4.61 | $3.88 | $4.62 | $5.25 | $2.08 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $641.00M | $1.72B | $1.42B | $1.01B | $2.28B | $2.83B |
| Accounts Receivable | $2.99B | $3.03B | $2.53B | $2.19B | $2.50B | $2.40B |
| Inventory | $3.89B | $3.84B | $3.27B | $3.22B | $2.87B | $2.74B |
| Accounts Payable | $1.97B | $1.90B | $1.64B | $1.70B | $1.79B | $1.35B |
| Current Assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B | $8.97B |
| Total Assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B |
| Current Liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B | $5.84B |
| Long-term Debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B | $17.22B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B | $23.77B |
| Retained Earnings | $16.62B | $16.14B | $15.54B | $15.16B | $13.83B | $12.79B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.43B | $3.84B | $2.99B | $2.94B | $4.65B | $3.54B |
| Investing Cash Flow | ($5.51B) | ($5.51B) | ($716.00M) | ($1.19B) | ($1.88B) | ($1.23B) |
| Financing Cash Flow | $2.09B | $2.09B | ($1.96B) | $22.00M | ($3.31B) | $22.00M |
| CapEx | $760.00M | $725.00M | $874.00M | $973.00M | $1.23B | $810.00M |
| Free Cash Flow | $2.67B | $3.12B | $2.12B | $1.96B | $3.42B | $2.73B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 45.4% | 45.2% | 42.2% | 44.9% | 46.6% | 44.3% |
| Operating margin | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% | 8.7% |
| EBITDA margin | 23.1% | 23.2% | 22.7% | 23.9% | 25.0% | 21.3% |
| Net margin | 7.7% | 8.4% | 7.7% | 9.4% | 10.3% | 5.1% |
| Free cash flow margin | 12.2% | 15.5% | 10.9% | 10.4% | 16.9% | 15.9% |
| FCF / Net income | 1.59 | 1.83 | 1.43 | 1.10 | 1.63 | 3.12 |
| R&D / Revenue | 5.8% | 5.9% | 6.4% | 6.7% | 6.6% | 6.4% |
| SG&A / Revenue | 24.2% | 24.1% | 24.4% | 25.0% | 24.0% | 25.3% |
| Effective tax rate | 10.8% | 15.0% | 8.2% | 7.7% | 6.7% | 11.3% |
| Return on assets | 3.0% | 3.0% | 2.8% | 3.4% | 3.9% | 1.6% |
| Return on equity | 6.6% | 6.6% | 5.8% | 7.0% | 8.8% | 3.7% |
| Return on invested capital | 5.3% | 4.7% | 4.8% | 5.4% | 6.4% | 3.2% |
| Liquidity | ||||||
| Current ratio | 1.11 | 1.17 | 1.31 | 1.04 | 1.33 | 1.54 |
| Quick ratio | 0.64 | 0.74 | 0.81 | 0.63 | 0.90 | 1.07 |
| Cash ratio | 0.08 | 0.19 | 0.21 | 0.13 | 0.34 | 0.48 |
| Leverage | ||||||
| Debt / Equity | 0.69 | 0.69 | 0.57 | 0.55 | 0.72 | 0.72 |
| Debt / Assets | 0.32 | 0.31 | 0.28 | 0.26 | 0.32 | 0.32 |
| Debt / EBITDA | 3.50 | 3.83 | 3.35 | 3.08 | 3.37 | 4.73 |
| Interest coverage | 4.2x | 4.5x | 4.7x | 5.7x | 6.0x | 2.8x |
| Equity multiplier | 2.18 | 2.21 | 2.05 | 2.09 | 2.28 | 2.27 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.39 | 0.35 | 0.37 | 0.36 | 0.38 | 0.32 |
| Inventory turnover | 3.06 | 2.88 | 3.42 | 3.22 | 3.78 | 3.48 |
| Days sales outstanding | 50d | 55d | 48d | 42d | 45d | 51d |
| Days inventory outstanding | 119d | 127d | 107d | 113d | 97d | 105d |
| Days payable outstanding | 60d | 63d | 53d | 60d | 60d | 52d |
| Cash conversion cycle | 109d | 119d | 101d | 96d | 81d | 104d |
| Valuation | ||||||
| P / E | 32.2x | 41.1x | 52.3x | 37.9x | 35.9x | 85.9x |
| P / B | 1.7x | 2.1x | 2.3x | 2.0x | 2.3x | 2.1x |
| P / S | 1.9x | 2.7x | 3.0x | 2.7x | 2.7x | 2.9x |
| EV / EBITDA | 11.8x | 15.2x | 16.4x | 14.0x | 13.8x | 17.8x |
| Growth | ||||||
| Revenue growth (YoY) | 8.2% | 4.2% | 2.7% | -6.8% | 18.3% | -1.0% |
| Revenue CAGR (3y) | 5.0% | -0.1% | 4.2% | 3.0% | 17.5% | 12.3% |
| Revenue CAGR (5y) | 5.0% | 3.1% | 9.2% | 9.3% | 10.2% | 10.7% |
| Gross profit growth (YoY) | 8.8% | 11.7% | -3.6% | -10.1% | 24.4% | 4.2% |
| Operating income growth (YoY) | 7.6% | 13.5% | -7.5% | -18.5% | 88.6% | -15.7% |
| Net income growth (YoY) | -1.6% | 14.9% | -16.6% | -15.0% | 139.4% | -29.1% |
| EPS growth (YoY) | -0.7% | 18.6% | -16.0% | -12.0% | 152.8% | -47.2% |
| EPS CAGR (3y) | -0.3% | -4.3% | 23.2% | 5.5% | 106.1% | -23.3% |
| EPS CAGR (5y) | 17.1% | 3.2% | 45.3% | 0.1% | 3.2% | -9.1% |
| FCF growth (YoY) | -14.4% | 47.4% | 7.7% | -42.5% | 25.2% | 15.0% |
| FCF CAGR (5y) | -0.4% | 5.6% | 1.4% | 1.5% | 12.9% | 19.2% |
| Book value growth (YoY) | -1.9% | 0.4% | 2.0% | 6.8% | -0.4% | 12.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$8.02B totalMedical$4.58B · 57.1%
Life Sciences$1.87B · 23.3%
Interventional$1.57B · 19.6%
Geographic
$13.63B totalEMEA$4.73B · 34.7%
Asia$3.09B · 22.7%
US$2.79B · 20.5%
Non Us$1.79B · 13.1%
Others Country$1.23B · 9.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing BECTON DICKINSON & CO against the 5 most active filers in the same SIC group.
Dividends
$3.51/share trailing 12 months · +12.2% YoY
| Ex-date | Per share |
|---|---|
| Mar 10, 2026 | $1.0500 |
| Dec 8, 2025 | $0.8255 |
| Sep 8, 2025 | $0.8176 |
| Jun 9, 2025 | $0.8176 |
| Mar 10, 2025 | $0.8176 |
| Dec 9, 2024 | $0.8176 |
| Sep 9, 2024 | $0.7469 |
| Jun 10, 2024 | $0.7469 |
| Mar 7, 2024 | $0.7469 |
| Dec 7, 2023 | $0.7469 |
| Sep 7, 2023 | $0.7154 |
| Jun 8, 2023 | $0.7154 |
| Mar 9, 2023 | $0.7154 |
| Dec 8, 2022 | $0.7154 |
| Sep 8, 2022 | $0.6840 |
| Jun 8, 2022 | $0.6840 |
| Mar 9, 2022 | $0.6673 |
| Dec 9, 2021 | $0.6673 |
| Sep 8, 2021 | $0.6366 |
| Jun 8, 2021 | $0.6366 |
| Mar 9, 2021 | $0.6366 |
| Dec 9, 2020 | $0.6366 |
| Sep 8, 2020 | $0.6059 |
| Jun 8, 2020 | $0.6059 |